苯并呋喃-7-羧酸 | 90484-22-3

• 物质功能分类: 有机原料 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并呋喃
• 中文名称: 苯并呋喃-7-羧酸
• 中文别名: N-BOC-(3S,4S)-二羟基-四氢吡咯
• 英文名称: benzofuran-7-carboxylic acid
• 英文别名: 1-benzofuran-7-carboxylic acid；7-benzofuranylcarboxylic acid
• CAS: 90484-22-3
• 化学式: C₉H₆O₃
• mdl: MFCD10000617
• 分子量: 162.145
• InChiKey: QMHILIQFOBNARN-UHFFFAOYSA-N

物化性质

• 沸点：
  325.6±15.0 °C(Predicted)
• 密度：
  1.363±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  50.4
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2932999099
• 危险性防范说明：
  P280,P305+P351+P338
• 危险性描述：
  H302

制备方法与用途

苯并呋喃-7-羧酸主要用于科研领域作为研究用化合物。

反应信息

• 作为反应物：
  描述：

  苯并呋喃-7-羧酸 在 草酰氯 、 N,N-二甲基甲酰胺 作用下， 以 二氯甲烷 为溶剂， 以100 %的产率得到benzofuran-7-carboxylic acid chloride
  参考文献：
  名称：

  通过多功能手性酰胺定向策略进行不对称钌催化的 C−H 活化

  摘要：

  在钌 (II) 催化的不对称 C−H 活化的背景下研究了一种多功能手性酰胺导向基团。已实现六次转化，提供了一系列有价值的手性产物。利用该工具，完成了许多天然产物和生物活性化合物（例如 Montroumarin、Cyclosporone E、Cyclosporone Q、Concentricolide、Chuangxinol 和 Eleutherol）的简明合成。

  DOI：

  10.1002/anie.202316741
• 作为产物：
  描述：

  3-烯丙基-2-羟基苯甲酸甲酯 在 氢氧化钾 、 二甲基硫 、 磷酸 、 臭氧 作用下， 以 乙醇 为溶剂， 反应 5.67h， 生成 苯并呋喃-7-羧酸
  参考文献：
  名称：

  Aminoalkylindoles: Structure-Activity Relationships of Novel Cannabinoid Mimetics

  摘要：

  Aminoalkylindoles (AAIs) are a novel series of cannabinoid receptor ligands. In this report we disclose the structural features of AAIs which are important for binding to this receptor as measured by inhibition of binding of [H-3]Win 55212-2 (5). Functional activity in the mouse vas deferens is also noted and used to distinguish agonists from potential antagonists. The key structural features for potent cannabinoid activity in this series are a bicyclic (naphthyl) substituent at the 3-position, a small (II) substituent at the 2-position, and an aminoethyl (morpholinoethyl) substituent at the 1-position. A 6-bromo analog, Win 54461 (31), has been identified as a potential cannabinoid receptor antagonist. Modeling experiments were done to develop a pharmacophore and also to compare AAI structures with those of classical cannabinoids. The fact that the cannabinoid AAIs arose out of work on a series of cyclooxygenase inhibitors makes sense now that an endogenous cannabinoid ligand has been identified which is a derivative of arachidonic acid. Because of their unique structures and physical properties, AAIs provide useful tools to study the structure and function of the cannabinoid receptor(s).

  DOI：

  10.1021/jm00016a013

文献信息

• Monoacylglycerol Lipase Modulators
  申请人：Janssen Pharmaceutica NV

  公开号：US20200102303A1

  公开（公告）日：2020-04-02

  Fused compounds of Formula (I) and Formula (II), pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to major depressive disorder, treatment resistant depression, anxious depression, bipolar disorder), cancers and eye conditions. Wherein R 1 , R 2 , R 2a , R 3 , R 3a , R 4 , and R 4a are defined herein.

  化合物的结构式（I）和结构式（II），含有它们的药物组合物，制备它们的方法，以及使用它们的方法，包括用于治疗与MGL调节相关的疾病状态、紊乱和病况的方法，例如与疼痛、精神障碍、神经障碍（包括但不限于重性抑郁障碍、治疗抵抗性抑郁症、焦虑性抑郁症、躁郁症）、癌症和眼部疾病相关的方法。 其中R1、R2、R2a、R3、R3a、R4和R4a在此处定义。
• Aminoalkoxybenzoyl-benzofuran or benzothiophene derivatives, method for preparing same and compositions containing same
  申请人：——

  公开号：US20040010011A1

  公开（公告）日：2004-01-15

  The invention relates to benzofuran or benzothiophene derivatives of general formula: 1 These compounds are of use as medicinal products, in particular in the treatment of pathological syndromes of the cardiovascular system.

  这项发明涉及一般式为苯并呋喃或苯并噻吩衍生物的化合物：1。这些化合物可用作药物产品，特别是用于治疗心血管系统病理综合征。
• Benzo-furan derivative
  申请人：Tanabe Seiyaku Co., Ltd.

  公开号：US04829067A1

  公开（公告）日：1989-05-09

  Novel benzo-furan(or -thiophene) derivative of the formula: ##STR1## wherein R.sup.1 is hydrogen atom, a lower alkyl group, a cycloalkyl group, a phenyl-lower alkyl group or a substituted or unsubstituted phenyl group, R.sup.2 is hydrogen atom, a lower alkyl group, an acyl group or phenyl group, R.sup.3 is hydrogen atom, a halogen atom, nitro group, a lower alkoxy group, amino group or an acylamino group, R.sup.4 is a group of the formula: ##STR2## A is a lower alkylene group optionally substituted with hydroxy group, B is single bond or a lower alkylene group, one of R.sup.5 and R.sup.6 is hydrogen atom or a lower alkyl group and the other is a lower alkyl group or a phenyl-lower alkyl group, or R.sup.5 and R.sup.6 combine together with adjacent nitrogen atom to form a heteromonocyclic group, R.sup.7 is a lower alkyl group, X is oxygen atom or sulfur atom, Y is oxygen atom, imino group, a lower alkylimino group or a phenyl-lower alkylimino group and a salt thereof are disclosed. Said compound (I) and a salt thereof have a potent inhibitory activity against reflective contraction of urinary bladder.

  一种新型苯并呋喃（或噻吩）衍生物的化学式如下：##STR1## 其中R.sup.1是氢原子、低碳烷基、环烷基、苯基-低碳烷基或取代或未取代的苯基，R.sup.2是氢原子、低碳烷基、酰基或苯基，R.sup.3是氢原子、卤素原子、硝基、低碳氧基、氨基或酰氨基，R.sup.4是下式的基团：##STR2## A是可选择地取代羟基的低碳烷基，B是单键或低碳烷基，R.sup.5和R.sup.6中的一个是氢原子或低碳烷基，另一个是低碳烷基或苯基-低碳烷基，或者R.sup.5和R.sup.6与相邻的氮原子结合形成杂单环基团，R.sup.7是低碳烷基，X是氧原子或硫原子，Y是氧原子、亚胺基、低碳烷基亚胺基或苯基-低碳烷基亚胺基以及其盐。所述化合物（I）及其盐对尿道膀胱反射收缩具有强大的抑制活性。
• 3-thienyl and 3-furanyl pyrrolidine modulators of chemokine receptor activity
  申请人：Merck & Co., Inc.

  公开号：US06303593B1

  公开（公告）日：2001-10-16

  The present invention is directed to pyrrolidine compounds of the formula I: (wherein R1, R2, R3, R4c, R4d, and R4f are defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the chemokine receptors CCR-3 and/or CCR-5.

  本发明涉及式I的吡咯烷化合物（其中R1、R2、R3、R4c、R4d和R4f在此处定义），这些化合物可用作趋化因子受体活性的调节剂。具体而言，这些化合物可用作趋化因子受体CCR-3和/或CCR-5的调节剂。
• 4-Oxooctahydroquinoline-1(2H)-carboxamides as hepatitis B virus (HBV) capsid core protein assembly modulators
  作者：Nicky Hwang、Haiqun Ban、Shuo Wu、Kelly McGuire、Ellen Hernandez、Junjun Chen、Qiong Zhao、Manasa Suresh、Benjamin Blass、Usha Viswanathan、John Kulp、Jinhong Chang、Jason Clement、Stephan Menne、Ju-Tao Guo、Yanming Du

  DOI：10.1016/j.bmcl.2021.128518

  日期：2022.2

  protein, the building block of the HBV capsid, plays multiple roles in viral replication, and is an attractive target for development of antiviral agents with a new mechanism of action. In addition to the heteroaryldihydropyrimidines (HAPs), sulfamoylbenzamides (SBAs), dibenzothiazepine derivatives (DBTs), and sulfamoylpyrrolamides (SPAs) that inhibit HBV replication by modulation of viral capsid assembly

  乙型肝炎病毒 (HBV) 核心蛋白是 HBV 衣壳的组成部分，在病毒复制中发挥多种作用，是开发具有新作用机制的抗病毒药物的有吸引力的靶标。除了杂芳基二氢嘧啶 (HAP)、氨磺酰苯甲酰胺 (SBA)、二苯并噻氮衍生物 (DBT) 和氨磺酰吡咯酰胺 (SPA)，它们通过调节病毒衣壳组装来抑制 HBV 复制，目前正在进行慢性乙型肝炎 (CHB) 治疗的临床试验), 其他具有调节 HBV 衣壳组装活性的化学结构也已被探索。在这里，我们描述了我们对源自高通量筛选的苯甲酰胺的持续优化。发现了一种具有缺电子非平面核心结构的新型双环甲酰胺先导化合物。